Skip to content

Study · Randomized controlled trial · n = 15 · 2013

5 results

Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans.

Striepens N, Kendrick KM, Hanking V, Landgraf R, Wüllner U, Maier W, Hurlemann R

Scientific reports6 Dec 2013Cited by 366 (Europe PMC)

PMID24310737 (opens in a new tab)PMCIDPMC3853684 (opens in a new tab)DOI10.1038/srep03440 (opens in a new tab)PepBankPUB-24310737
Read at sourcePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In human subjects, intranasal oxytocin significantly increased plasma oxytocin levels compared with placebo.

    In plain wordsIn people, oxytocin sprayed into the nose raised oxytocin levels in the blood compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreasePlasma oxytocin concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    we have shown that oxytocin levels significantly increased in both plasma and CSF.
    1 context sentence
    Summary · context
    Here using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n = 11) or placebo (n = 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In human subjects, intranasal oxytocin significantly increased cerebrospinal fluid oxytocin levels compared with placebo.

    In plain wordsIn people, oxytocin sprayed into the nose raised oxytocin levels in the fluid around the brain compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseCSF oxytocin concentration
    Study

    n = 15

    Comparator
    Placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Source sentences

    Summary
    we have shown that oxytocin levels significantly increased in both plasma and CSF.
    1 context sentence
    Summary · context
    Here using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n = 11) or placebo (n = 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.
  3. 03HumanRandomized controlled trialPharmacokinetics

    Plasma oxytocin peaked 15 min after intranasal administration and decreased after 75 min.

    In plain wordsOxytocin levels in the blood peaked 15 minutes after the nasal dose and fell after 75 minutes.

    Peptide
    Oxytocin
    Outcome
    Not applicableTime course of plasma oxytocin
    Study

    n = 15

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    Time to peak plasma concentration
    15 min
    plasma

    Source sentences

    Summary
    oxytocin plasma concentrations peaked at 15 min after intranasal administration and decreased after 75 min
    1 context sentence
    Summary · context
    Here using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n = 11) or placebo (n = 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.
  4. 04HumanRandomized controlled trialPharmacokinetics

    CSF oxytocin concentrations took up to 75 min after intranasal administration to reach a significant level.

    In plain wordsOxytocin in the fluid around the brain took up to 75 minutes to reach a significant level after the nasal dose.

    Peptide
    Oxytocin
    Outcome
    Not applicableTime course of CSF oxytocin
    Study

    n = 15

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    Time to significant CSF level
    ≤ 75 min
    CSF

    Source sentences

    Summary
    CSF concentrations took up to 75 min to reach a significant level.
    1 context sentence
    Summary · context
    Here using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n = 11) or placebo (n = 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.
  5. 05HumanRandomized controlled trialPharmacokinetics

    There was no correlation between plasma and CSF oxytocin concentrations after intranasal administration.

    In plain wordsBlood and brain-fluid oxytocin levels did not track each other after the nasal dose.

    Peptide
    Oxytocin
    Outcome
    No significant changeCorrelation between plasma and CSF oxytocin
    Study

    n = 15

    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    24 IU · intranasalAs given in this study (human).

    Measurements

    Correlation coefficient r
    < 0.1 r
    plasma vs CSF

    Source sentences

    Summary
    Moreover, there was no correlation (r = <0.10) between oxytocin plasma and CSF concentrations.
    1 context sentence
    Summary · context
    Here using combined blood and cerebrospinal fluid (CSF) sampling in subjects receiving either 24 IU of oxytocin (n = 11) or placebo (n = 4) we have shown that oxytocin levels significantly increased in both plasma and CSF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 1/2NCT03863288

Dose Response Relationship of Oxytocin on Irritability in Youths

University of Nebraskan = 6018 Feb 2022 to 27 Feb 2024

Irritable Mood

Trial pageClinicalTrials.govUpdated 14 Mar 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 01:30 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:49 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.